Vivos Therapeutics’ SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea

LITTLETON, Colo., June 14, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) (“Vivos” or “the Company”), a revenue-generating medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today announced that the Company presented positive results from a retrospective study with Vivos patients at this year’s SLEEP 2022, the annual meeting of the Associated Professional Sleep Societies, a joint venture of the American Academy of Sleep Medicine and Sleep Research Society. On June 6, 2022, Dr. Seth Heckman, Vivos Medical Advisory Board member, led a presentation, titled, “Non-Surgical Maxillary Expansion Using A Novel Oral Appliance System.”